Long-Term Survival of Patients With Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)

(2018) Brigette B.Y. Ma et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study

(2017) Chiun Hsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Maintenance of antiangiogenic and antitumor effects by orally active low-dose capecitabine for long-term cancer therapy

(2017) Yin Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Safety profile of capecitabine as maintenance treatment after induction with XELOX or FOLFOX in metastatic colorectal cancer patients

(2016) C. Cremolini et al.   ANNALS OF ONCOLOGY

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

(2016) Li Zhang et al.   LANCET

Nasopharyngeal carcinoma

(2016) Melvin L K Chua et al.   LANCET

Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation

(2015) D. E. Spratt et al.   CANCER RESEARCH

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

(2015) Nick Thatcher et al.   LANCET ONCOLOGY

Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial

(2015) Ricard Mesía et al.   LANCET ONCOLOGY

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Retrospective Analysis of 234 Nasopharyngeal Carcinoma Patients with Distant Metastasis at Initial Diagnosis: Therapeutic Approaches and Prognostic Factors

(2014) Lei Zeng et al.   PLoS One

Efficacy of Nimotuzumab Combined with Docetaxel–Cisplatin–Fluorouracil Regimen in Treatment of Advanced Oral Carcinoma

(2013) Jian Meng et al.   CELL BIOCHEMISTRY AND BIOPHYSICS

Prospective Study of Tailoring Whole-Body Dual-Modality [18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography With Plasma Epstein-Barr Virus DNA for Detecting Distant Metastasis in Endemic Nasopharyngeal Carcinoma at Initial Staging

(2013) Lin-Quan Tang et al.   JOURNAL OF CLINICAL ONCOLOGY

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

(2013) Jan B Vermorken et al.   LANCET ONCOLOGY

Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis

(2013) Ming-Yuan Chen et al.   Chinese Journal of Cancer

Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma

(2012) Ying Jin et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Combined High-dose Radiation Therapy and Systemic Chemotherapy Improves Survival in Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer

(2011) Shaojun Lin et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma

(2011) B. B. Y. Ma et al.   ANNALS OF ONCOLOGY

8558 POSTER An Open, Multicenter Clinical Study of Cetuximab Combined With Intensity Modulated Radiotherapy Plus Concurrent Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma

(2011) T. Lin et al.   EUROPEAN JOURNAL OF CANCER

Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

(2011) Alessandra Gennari et al.   JOURNAL OF CLINICAL ONCOLOGY

Nimotuzumab with chemoradiation confers a survival advantage in treatment-naïve head and neck tumors over expressing EGFR

(2010) Chetana Basavaraj et al.   CANCER BIOLOGY & THERAPY

Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck

(2010) Marta Osorio Rodríguez et al.   CANCER BIOLOGY & THERAPY

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

(2009) James A Bonner et al.   LANCET ONCOLOGY

Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma

(2008) Yu-Hong Li et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE